Ask a Fool: What Will Belviq's Launch Do for Arena?
Jun 26th 2013 5:36PM
Updated Jun 26th 2013 5:38PM
In the following video, Motley Fool health-care analyst Max Macaluso takes a question from a Fool reader, who writes, "How do you think the initial sales of Arena Pharmaceuticals' Belviq will be?"
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Ask a Fool: What Will Belviq's Launch Do for Arena? originally appeared on Fool.com.Max Macaluso, Ph.D. and The Motley Fool have no position in any stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.